Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiethylperazine theranostic trial in early Alzheimer's disease
2022-501137-23-00Phase 2Authorised
- Sponsor
- Immungenetics AG
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of thiethylperazine in Alzheimer's disease (AD) (2 arms), sponsored by Immungenetics AG. Planned start Nov 2022; status: authorised.
02
Drugs
thiethylperazine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-501137-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501137-23-00.